Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol

Top 10 HIV/AIDS-Related Clinical Developments of 2011

December 1, 2011

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  Next > 

6. No Go Isentress QD

For once-a-day Isentress, the story is less one of audacity than of hope. Twice-a-day regimens are now considered by most providers and many patients to be one dose too many, and there was a real desire to see otherwise-user-friendly Isentress join the other preferred ranks by becoming once a day. Pharmacologic data from Merck, the maker of the drug, suggested that the business end of Isentress was intracellular and that plasma levels were not the best indicator of what this integrase inhibitor could do. Therefore, it was with confidence that the QDMRK trial was launched.14

Advertisement

In this placebo-controlled study, 775 treatment-naive patients were randomized to Isentress once a day versus twice a day, both in combination with Truvada. At baseline, 39 percent of the treated patients had viral loads of more than 100,000 copies/mL and 24 percent had CD4+ cell counts of fewer than 200 cells/µL. Of the once-daily group, 83 percent had virological response, versus 89 percent in the twice-daily group (difference: -5.7 percent, 95% CI: -10.7 to -0.83; P = .044). Therefore, once-daily dosing of Isentress was inferior to twice-daily dosing of the drug. The difference in responses was even greater among those with baseline viral loads over 100,000 copies/mL: 74 percent versus 84 percent in the once-daily and twice-daily arms, respectively (difference: -9.9 percent, 95% CI -19 to -0.8). A similar splay was seen in those with CD4+ cell counts below 200 cells/µL at entry.

Of the 53 recipients of once-daily Isentress with virological failure, 22 (42 percent) never responded and 31 (58 percent) had viral rebound. Of the 35 recipients of twice-daily Isentress with virological failure, 14 (40 percent) never responded and 21 (60 percent) had viral rebound. Integrase mutations were more commonly seen in the once-daily arm, as was resistance to Emtriva (emtricitabine, FTC).

Serious adverse events were reported in 7 percent of the once-daily recipients and 10 percent of the twice-daily recipients, and adverse events leading to discontinuation occurred in four patients (1 percent) in each group.

The Bottom Line

If wishing alone had mattered, the results of this study would have been different. But it was not to be. Again, it is not that once-a-day Isentress was awful. Rather, it was not as good as twice-a-day dosing of the drug. For those with baseline viral loads of over 100,000 copies/mL or CD4+ cell counts below 200 cells/µL, there was a more substantial difference, which would preclude most use of once-daily Isentress in such patients.

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  Next > 

This article was provided by TheBody.com.
 
See Also
10 HIV/AIDS Stories That Defined 2011 in the US
What's the Buzz? The Top 10 Stories on TheBody.com in 2011
Read More Articles From TheBody.com's 2011 HIV/AIDS Year in Review
More News and Research on HIV Medications for HIV Prevention

Reader Comments:

Comment by: esme (south africa) Wed., Feb. 8, 2012 at 2:36 am EST
I am greatfull that the Drop of41% HIV/AIDS are announce in the Health Dep in US, but in South Africa
education and treadment after HIV/AIDS are diagnose are short coming we need more funds and help!
Reply to this comment


Comment by: Michael Marco (New York, NY) Mon., Jan. 16, 2012 at 6:45 pm EST
David...wonderful job on this top-10 round-up. Beautifully succinct and thoroughly informative. Cheers...Michael
Reply to this comment


Comment by: nisha (delhi,india) Mon., Dec. 12, 2011 at 11:40 pm EST
please invent the the medicine which can cure hiv completely... Need it despirately..thanks... And best luck...
Reply to this comment


Comment by: Dominic (Brighton, England, UK.) Fri., Dec. 2, 2011 at 8:22 am EST
David, many thanks for this very helpful round-up.

It's disappointing for me to perceive from what you have reported that we are nowhere as near "the cure" as some reports in various reputable papers over the course of this year have suggested. But this I can accept.

Happy Yule and a successful 2012 to you!
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 
Advertisement